REGENXBIO/$RGNX
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About REGENXBIO
Regenxbio Inc is a clinical-stage biotechnology company focused on the development of gene therapy treatments. Its product candidates are designed to deliver genes to cells to address genetic defects or enable the production of therapeutic proteins. The company is developing a pipeline of investigational gene therapy treatments using its NAV Technology Platform based on adeno-associated virus (AAV) vectors. Its internal research and development programs are focused on therapies for retinal, neuromuscular, and neurodegenerative diseases.
- Ticker
- $RGNX
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 371
- Headquarters
- Rockville, United States
- Website
- www.regenxbio.com
REGENXBIO Metrics
BasicAdvanced
$472M
-
-$3.77
0.93
-
Price and volume
Market cap
$472M
Beta
0.93
52-week high
$16.19
52-week low
$5.46
Average daily volume
1.5M
Financial strength
Current ratio
2.858
Quick ratio
2.701
Long term debt to equity
3.015
Total debt to equity
3.49
Interest coverage (TTM)
-3.91%
Profitability
EBITDA (TTM)
-148.777
Gross margin (TTM)
-44.95%
Net profit margin (TTM)
-112.58%
Operating margin (TTM)
-94.08%
Revenue per employee (TTM)
$470,000
Management effectiveness
Return on assets (TTM)
-21.20%
Return on equity (TTM)
-137.63%
Valuation
Price to revenue (TTM)
2.138
Price to book
5.4
Price to tangible book (TTM)
5.4
Price to free cash flow (TTM)
-1.494
Free cash flow yield (TTM)
-66.93%
Free cash flow per share (TTM)
-4.785
Growth
Revenue change (TTM)
12.00%
Earnings per share change (TTM)
9.66%
3-year revenue growth (CAGR)
21.63%
10-year revenue growth (CAGR)
35.52%
3-year earnings per share growth (CAGR)
-15.87%
10-year earnings per share growth (CAGR)
7.69%
What the Analysts think about REGENXBIO
Analyst ratings (Buy, Hold, Sell) for REGENXBIO stock.
Analyst projections of the future price of REGENXBIO stock.
Bulls say / Bears say
RGX-202 met its Phase 3 primary endpoint, with 93% of evaluable participants reaching the prespecified microdystrophin threshold; early one-year functional results also favoured treatment over external controls. That gives REGENXBIO a credible potential Duchenne approval catalyst. (NeurologyLive)
The AbbVie-partnered retinal programme offers another late-stage growth opportunity: REGENXBIO reported durable vision and treatment-burden results in longer-term wet AMD follow-up, with pivotal wet AMD data expected in the fourth quarter of 2026. (REGENXBIO)
The company’s post-July cash position of about $313 million is expected to fund operations into the fourth quarter of 2027, covering key planned Duchenne and retinal milestones and easing near-term financing pressure. (REGENXBIO)
The FDA placed RGX-121 on clinical hold after spine MRI findings in five participants, and the company no longer expects to resubmit its application in the near term. This removes a potential approval catalyst and leaves the programme’s timing and prospects uncertain. (BioPharma Dive)
RGX-202’s pivotal cohort included two treatment-related serious events: myocarditis and liver injury, although both resolved. These events add safety and regulatory risk to the company’s lead Duchenne opportunity. (NeurologyLive)
The cash runway depends partly on a one-off AbbVie milestone and proceeds from a share offering, while US ZOLGENSMA royalties fell after patent expiry and the company continues to incur losses. That leaves future funding and dilution risks if development or launches take longer than planned. (SEC)
Data summarised monthly by Lightyear AI. Last updated on 17 Oct 2026.
REGENXBIO Financial Performance
Revenues and expenses
REGENXBIO Earnings Performance
Company profitability
Upcoming events
No upcoming events
REGENXBIO News
AllArticlesVideos
Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of REGENXBIO Inc. (RGNX)
Business Wire2 months ago
Regenxbio Stock Sinks 22% Following Surprise Finding in Gene Therapy Trial
Barrons2 months ago
FDA places clinical hold on Regenxbio's gene therapy for Hunter Syndrome
Reuters2 months ago
Funds containing REGENXBIO
Fund name | Fund size | $RGNX weighting |
|---|---|---|
iShares Healthcare Innovation£DRDR | $1.3B | 0.03% |
iShares Healthcare Innovation$HEAL | $1.3B | 0.03% |
iShares Nasdaq US Biotechnology$BTEC | $1.1B | 0.03% |
iShares Healthcare Innovation€2B78 | $1.2B | 0.03% |
iShares Nasdaq US Biotechnology£BTEK | $1.1B | 0.03% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.